TC
FATE icon

TFS Capital’s Fate Therapeutics FATE Stock Holding History

TFS Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-34,107
Closed -$111K – 119
2017
Q2 		$111K Sell
34,107
-20,491
-38% -$78.5K 0.04% 536
2017
Q1 		$248K Buy
+54,598
New +$200K 0.08% 418
2016
Q3 		– Sell
-20,925
Closed -$36K – 817
2016
Q2 		$36K Buy
+20,925
New +$37.9K 0.01% 927
2016
Q1 		– Sell
-32,495
Closed -$110K – 1021
2015
Q4 		$110K Sell
32,495
-88,656
-73% -$373K 0.01% 648
2015
Q3 		$646K Buy
121,151
+39,354
+48% +$269K 0.06% 447
2015
Q2 		$529K Buy
+81,797
New +$489K 0.05% 507

Other funds holding FATE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

TFS Capital's FATE Position: Q3 2017 in Review

TFS Capital sold out of Fate Therapeutics (FATE) in Q3 2017, closing a stake of 34,107 shares — an estimated $111K sold.

TFS Capital first reported a position in FATE in Q2 2015 and held it in 6 quarters. The position peaked at $646K in Q3 2015. 74 funds tracked by Wall St. Rank hold FATE as of Q3 2017.

  • TFS Capital reported no remaining Fate Therapeutics position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 34,107 Fate Therapeutics shares in Q3 2017, an estimated $111K.
  • TFS Capital first reported a position in Fate Therapeutics in Q2 2015 and held it in 6 quarters.
  • TFS Capital's Fate Therapeutics position peaked at $646K in Q3 2015.
  • 74 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.